2017 American Transplant Congress
Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…2017 American Transplant Congress
Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.
Introduction: The new KAS aims to improve access to transplantation for HS patients, specifically CPRA 99-100%. Our center has extensive experience w. DES to improve…2017 American Transplant Congress
Prognostic Tools to Choose Candidates for Successful Desensitization.
1Northwestern University, Chicago, IL; 2Johns Hopkins, Baltimore, MD
Antibodies to donor HLA antigens are a barrier to solid organ transplantation. Strategies to desensitize patients have improved, but the ability to predict response to…2016 American Transplant Congress
Impact of the New Kidney Allocation System on Highly Sensitized Patients: Single Center Report.
Background: Highly sensitized patients (HSP) with calculated Panel Reactive Antibody (cPRA) >80% are known to have extensive waiting time on UNOS list. The new kidney…2016 American Transplant Congress
Neuro-invasive Saint Louis Encephalitis Virus (SLEV) Infection in Solid Organ Transplant Recipients in a Non-Endemic Area.
Infectious Disease, Mayo Clinic Arizona, Phoenix, AZ.
Background:In the summer of 2015, three prior solid organ transplant recipients developed meningoencephalitis suggestive of West Nile virus (WNV) infection in the Phoenix area with…2016 American Transplant Congress
Donor Specif Antibody (DSA) Kinetics in Patients with Antibody Mediated Rejection (AMR) Treated with Plasmapheresis and Bortezomib.
Backgroud: The best choice to treat AMR is not supported by several evidences, and recently the interest in drugs as Bortezomib has improved. Aim: Evaluted…2016 American Transplant Congress
Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome.
Introduction: Monoclonal antibodies that disrupt CD40/CD40 ligand (CD40L) interactions are likely to have utility in human transplantation. However, the extent of the immunosuppressive effects of…2016 American Transplant Congress
The Preventive and Therapeutic Effect of Immunoglobulin on Infectious Complications in Donation After Cardiac Death Liver Transplant Recipients: A Prospective Randomized Controlled Study.
Aims: To prospectively investigate the preventive and therapeutic effect of immunoglobulin on infectious complications in DCD liver transplant recipients, and synthetically evaluate its influence on…2016 American Transplant Congress
Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.
Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN.
IntroductionThe hypothesis of this study was that the long-term outcomes in liver transplant (LTx) patients with hepatitis B virus (HBV) who were treated with nucleos(t)ide…2016 American Transplant Congress
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…
American Transplant Congress abstracts